• 作者：Carolin Cornelius^a ; Katrin Schö ; neweis^b ; Fanny Georgi^b ; Milena Weber^a ; Verena Niederberger^c ; Petra Zieglmayer^d ; Katarzyna Niespodziana^a ; Michael Trauner^e ; Harald Hofer^e ; Stephan Urban^b ; ^f ; Rudolf Valenta^a ; ^{rudolf.valenta@meduniwien.ac.at" class="auth_mail" title="E-mail the corresponding author}
• 关键词：HBV ; hepatitis B virus ; HBcAg ; hepatitis B virus core antigen ; HBeAg ; hepatitis B virus e antigen ; HBsAg ; hepatitis B virus surface antigen ; NTCP ; sodium-taurocholate co-transporting polypeptide ; AIT ; allergen-specific immunotherapy
• 刊名：EBioMedicine
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：11
• 期：Complete
• 页码：58-67
• 全文大小：1313 K

•

BM32 is a recombinant allergy vaccine consisting of the preS domain of the large envelope protein of hepatitis B virus (HBV) and allergen-derived peptides.

•

Vaccination of allergic patients with BM32 induced preS-specific antibodies which inhibit hepatitis B infection in vitro.

•

BM32 may be useful as therapeutic vaccine in HBV-infected patients.

Infection with HBV remains a major cause of morbidity and mortality worldwide. Conventional HBV vaccines, consisting of SHBs particles solely, do not elicit adequate antibody production in 5–10% of vaccines and there is a need for therapeutic HBV vaccines. We have engineered an allergy vaccine which consists of allergen-derived peptides fused to the preS domain of the large envelope protein of HBV. Here we show that vaccination of allergic patients with this vaccine induces antibodies which protect against HBV infection in vitro. The preS-containing allergy vaccine may thus be also useful for therapeutic vaccination of HBV-infected patients.